Search Results - "WANG, Ling Z"

Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research Group by YEO, Winnie, CHUNG, Hyun C, HUI, Edwin P, JEUNG, Hei C, ROH, Jae K, YU, Simon C. H, TO, Ka F, QIAN TAO, MA, Brigette B, CHAN, Anthony W. H, TONG, Joanna H. M, ERLICHMAN, Charles, CHAN, Stephen L, CHAN, Anthony T. C, GOH, Boon C, WANG, Ling Z, LIM, Robert, PICUS, Joel, BOYER, Michael, MO, Frankie K. F, KOH, Jane, RHA, Sun Y

“…Epigenetic aberrations have been reported in hepatocellular carcinoma (HCC). In this study of patients with unresectable HCC and chronic liver disease,…”
Get full text

Phase I trial of fixed dose-rate gemcitabine in combination with carboplatin in chemonaive advanced non-small-cell lung cancer: a Cancer Therapeutics Research Group study by SOO, Ross A, LIM, Hong L, WANG, Ling Z, LEE, How S, MILLWARD, Michael J, TOK, Lay T, LEE, Soo C, LEHNERT, Manfred, GOH, Boon C

“…To determine the maximally tolerated dose (MTD) of gemcitabine administered at a fixed dose-rate of 10 mg/m(2) per min in combination with fixed dose…”
Get full text